An oncolytic HAdV-5 with reduced surface charge combines diminished toxicity and improved tumor targeting
2024

Modified Adenovirus for Better Cancer Treatment

Sample size: 12 publication 10 minutes Evidence: moderate

Author Information

Author(s): Wienen Frederik, Nilson Robin, Allmendinger Ellen, Peters Sarah, Barth Thomas F.E., Kochanek Stefan, Krutzke Lea

Primary Institution: Ulm University

Hypothesis

Can a genetically modified adenovirus improve tumor targeting and reduce toxicity in cancer therapy?

Conclusion

The modified adenovirus showed reduced liver toxicity and improved tumor targeting in mice.

Supporting Evidence

  • The modified adenovirus showed a 29-fold improved tumor-to-liver ratio compared to the control.
  • Intravenous injection of the modified virus was well tolerated in mice.
  • Significantly reduced off-target organ tropism was observed with the modified virus.

Takeaway

Scientists created a special virus that can attack cancer cells better and hurt the liver less when given to mice.

Methodology

The study involved genetic modification of adenovirus, in vitro and in vivo testing in tumor-bearing mice, and analysis of biodistribution and toxicity.

Potential Biases

Potential bias in the interpretation of results due to the use of a single animal model.

Limitations

The study was conducted in immunodeficient mice, which may not fully represent human responses.

Participant Demographics

NSG mice were used for the experiments.

Statistical Information

P-Value

p<0.05

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1016/j.omton.2024.200909

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication